INS and type 2 diabetes mellitus: Other studies have shown that both exogenous [27,29,30] and endogenous insulin (C-peptide immunoreactivity after intravenous glucagon injection) [30] have an impact on lowering the BMR of patients with T2DM, probably mediated by the suppression of glucose production by insulin.